• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Harmony Is Seen Rallying to $0.0150

Harmony (ONE) is down 4.3% to $0.0104 this week, underperforming Bitcoin (BTC), which slipped 1.0% to $114,978. The token is once again testing the strong $0.0100 support that has held since January 2021. Over the past five months, prices have consolidated in a narrowing range around this level, a pattern that typically precedes a strong breakout. Given the proximity to firm support, the move is more likely to the upside, with $0.0150 as the key resistance target. The Federal Reserve’s upcoming decision could act as the trigger for such a move.

640
AbbVie Has More Room for Appreciation

Shares of AbbVie pharmaceuticals hit an all-time record this week. This nearly $400 billion capitalized stock closed at $220.22 on September 11, up 4% from the previous day's performance, with an intraday high being at $221.76. The rise of the pharma sector is not as impressive as for so many cases in AI industry. On average, this process could be called rather restorative, even for big pharma stocks, but Abbvie as a real giant of the sector is a pleasant exception, having added about 30% from April's local lows corresponding to the tariff storm. And it has room for additional appreciation by market crowds and experts in the nearest 6 weeks before its scheduled quarterly earnings call on October 24.

Historically, Humira prescription drug to reduce the signs and symptoms of moderate to severe rheumatoid arthritis has been the crown jewel of AbbVie's commercial success, with its annual revenue reaching extraordinary heights around $20 billion globally. This was once Abbvie's best-selling drug, now battling severe competition from cheaper biosimilars produced by rivals since 2023. It has been reported in the mid-week, however, that no generic competition for Abbvie's currently blockbuster immunology drug Rinvoq used for similar diseases could be seen until 2037 at least. Again, the settlement with largest generic makers, which is subject to certain provisions in the U.S., is going to prevent sales erosion of Rinvoq within this 12-year timeframe, marking a 4-year extension compared to previous public estimates. Chris Schott at JP Morgan & Chase said the extension for its Rinvoq franchise gives AbbVie "years of runway on one of its key growth drivers" develop and test more now-experimental drugs ahead of any potential loss of exclusivity in the mid-2030s.

Humira is a biologic that blocks the so-called TNF (tumor necrosis factor), while Rinvoq scientifically is a JAK (Janus kinase) inhibitor that works inside cells to block signals causing inflammation. They also differ in how they are administered as Humira is an injection, whereas Rinvoq is a daily oral tablet. Rinvoq is also being tested for diseases such as alopecia areata, vitiligo, hidradenitis suppurativa and systemic lupus erythematosus. Rinvoq's annual sales for 2024 were $5.97 billion, a 46% increase from the prior year, while its Q2 2025 sales already reached $2.028 billion, another 41.8% of remarkable surplus YoY, accounting for more than 10% of total Abbvie sales. The figures contribute much to AbbVie's overall sales, with the combined sales of $15.42 billion in Q2 2025, with Rinvoq and Skyrizi projected to exceed $31 billion together by as early as 2027. Skyrizi is a brand name for a biologic injection to treat plaque psoriasis, its net sales reached $11.7 billion in 2024, a more than 50% increase vs 2023, and generated $4.4 billion only in the previous quarter to marking a 62% increase on an annual basis QoQ.

For us, the "fair value" of Abbvie could be estimated within the range of between $235 and $250 per share. We will wait and see when the opinion of the market crowd joins these reasonable estimates. This may happen before the end of this year or later in the spring of 2026, depending on investors' immediate response to the quarterly report in late October.

730
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Litecoin Is Struggling to Push Higher

Litecoin (LTC) is adding 1.5% to $115.74 this week, underperforming Bitcoin (BTC), which is rising by 3.4% to $114,487. LTC could be preparing for stronger moves as the SEC decision on a spot LTC-ETF approaches in October. Such approvals typically attract institutional investors and increase liquidity. Expectations of a dovish Fed stance may also support momentum. However, the token remains capped by the uptrend resistance at $125–126, which it unsuccessfully attempted to break in August. The nearest target is $120, and a decisive move above that level could open the way towards $140.

689
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
VeChain Is Building an Upside Momentum

VeChain (VET) is rising by 5.6% to $0.02470 this week, outperforming Bitcoin (BTC), which is adding 2.7% to $114,000. BTC climbed to $114,270 on Wednesday after U.S. producer price index data came in lower than expected, giving risky assets a boost. VET has closely tracked the benchmark’s move.

Now, investors are focused on U.S. consumer inflation data due Thursday. If it also surprises to the downside, BTC could extend gains toward the $117,000–$120,000 resistance zone. In that scenario, VET could finally break out of its three-month consolidation range, with upside potential first to $0.03000 and possibly further to $0.04000.

727
13

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors